ALDX Earnings Prediction
The chart below shows how ALDX performed 10 days before and after its earnings report, based on data from the past quarters. Typically, ALDX sees a -4.28% change in stock price 10 days leading up to the earnings, and a -1.81% change 10 days following the report. On the earnings day itself, the stock moves by +6.36%. This data can give you a slight idea of what to expect for the next quarter's release.
ALDX Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
--
--
--
Gross Margin
--
--
--
Operating Margin
--
--
--
Net Margin
--
--
--
EPS
-0.22
-18.52%
-12.00%
No Data Available
ALDX Earnings Analysis
Aldeyra Therapeutics, Inc. Corporation (ALDX.O) Earnings Conference Call
Positive
Positive Point: Aldeyra Therapeutics achieved significant milestones in 2022, including the submission of two new drug applications, Reproxalap for dry eye disease and ADX-2191 for primary vitreoretinal lymphoma, which was designated for priority review by the FDA.
Positive Point: The company's RASP modulation platform, particularly ADX-629, is advancing in Phase 2 clinical trials for various systemic indications, demonstrating potential activity across a range of diseases characterized by inflammation.
Positive Point: ADX-2191, the NDA for primary vitreoretinal lymphoma, has a PDUFA date of June 21, 2023, and if approved, will be the first FDA-approved drug for ocular lymphoma, addressing an unmet medical need in a patient population with limited treatment options.
Positive Point: Reproxalap, with a PDUFA date of November 23, 2023, showed positive results in a 12-month safety trial for dry eye disease, with statistically superior visual acuity improvements compared to the vehicle-treatment group, potentially positioning it as a differentiated product in the market.
Positive Point: Aldeyra's financial position remains strong, with $174.3 million in cash, cash equivalents, and marketable securities as of December 31, 2022, projected to fund operating expenses into the second half of 2024, including potential commercialization plans for Reproxalap and ADX-2191, if approved, and continued product development efforts.
Negative
Negative:
- Net loss for the year ended December 31, 2022, increased to $62.0 million from $57.8 million in 2021 due to higher research and development expenses, general and administrative expenses, and total operating expenses.
- Reproxalap's PDUFA date has been set for November 23, 2023, indicating a longer wait for potential approval and commercialization.
- Despite positive top-line results in the vehicle-controlled 12-month safety clinical trial for Reproxalap in dry eye disease patients, potential partnering discussions for Reproxalap are still ongoing, leaving uncertainty around commercialization efforts and market entry.
- The company's cash, cash equivalents, and marketable securities as of December 31, 2022, were $174.3 million, raising concerns about the funding timeline to support ongoing operations, commercialization plans, and product development initiatives until the second half of 2024.
